ClinicalTrials.gg
RecruitingNCT07427446Updated Feb 27, 2026

Dexmedetomidine-Midazolam vs. Ketamine-Midazolam on Emergence Delirium

A Phase 4 interventional study of Dexmedetomidine and Midazolam and Ketamine and Midazolam in Emergence Delirium, sponsored by Kasr El Aini Hospital. Recruiting at 1 site in Egypt. Open to participants aged 2 Years to 6 Years. Per ClinicalTrials.gov, last updated 2026-02-27.

Sponsored by Kasr El Aini Hospital · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
2 Years to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 83 studies testing dexmedetomidine in Emergence Delirium — 31 open to participants now, 32 under way, 2 of them phase 3. Dexmedetomidine · Emergence Delirium.

Planned enrollment
71st of 83
50 · median 100
Started
2026
with 15 others
Phase 4
31 of 83
10 open now
Primary completion
2026-12
later than 18 of 31 live
Registered
70th of 83
by date

Among the 83 studies testing dexmedetomidine in Emergence Delirium, this one is the 71st largest by planned enrollment, is one of 16 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 18 of the 31 other live ones, and was the 70th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

31 of the 83 studies testing dexmedetomidine in Emergence Delirium are open now, in 10 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 31 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 2 Years to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies testing dexmedetomidine in Emergence Delirium, or all of them as a file.
02

Study summary

Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups.

Group DM (Dexmedetomidine + Midazolam) and Group KM (Ketamine + Midazolam)

Read the detailed description

Fifty children undergoing heart catheterization without local anesthesia in the skin will be randomly divided into two groups.

Group DM (Dexmedetomidine + Midazolam) will receive dexmedetomidine 1 µg/kg IV over 10 minutes and midazolam 0.1 mg/kg IV as a bolus concomitant with induction, followed by a continuous infusion of dexmedetomidine at 0.5 µg/kg/h and midazolam at 0.1 mg/kg/h for maintenance.

Group KM (Ketamine + Midazolam) will receive ketamine 1 mg/kg IV and midazolam 0.1 mg/kg IV as a bolus for induction, followed by a continuous infusion of ketamine at 1 mg/kg/h and midazolam at 0.1 mg/kg/h.

03

Conditions studied

  • Emergence Delirium

Browse trials for

Keywords

  • Emergence delirium
  • Dexmedetomidine
  • Ketamine
  • Midazolam
  • sevoflurane
04

Who can participate

Ages eligible
2 Years to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Scheduled for elective cardiac catheterization under general anesthesia.

Exclusion criteria

Exclusion Criteria:

  • neurological disorder, psychiatric disease, or current psychoactive medication.
  • allergy.
  • significant systemic comorbidities.
05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine-Midazolam

    Children will receive Dexmedetomidine + Midazolam

    Drug: Dexmedetomidine and Midazolam

  • Active comparator
    ketamine-Midazolam

    Children will receive ketamine + Midazolam

    Drug: Ketamine and Midazolam

Interventions

06

What researchers measure

Primary outcomes

  1. Emergence delirium

    Incidence of emergence delirium assessed using the Pediatric Anesthesia Emergence Delirium PAED scale. The scale consists of five behavioral items, each rated on a 5-point scale from 0 to 4(Eye contact, Purposefulness, Awareness, Restlessness, Inconsolability),Total scores range from 0 to 20.A PAED score ≥10 will be considered a clinically significant ED.

    Time frame: 30 minutes post-anesthesia

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 10 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2026
First posted
Feb 23, 2026
StartActual
Feb 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Mar 2027
Last update
Feb 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07427446
Responsible party
Ahmed Mohamed Mohamed Elhaddad (Assisstent Professor, Kasr El Aini Hospital) — Principal investigator
First posted
Feb 23, 2026
Start date
Feb 1, 2026
Primary completion
Dec 2026 (estimated)
Completion
Mar 2027 (estimated)
Last update
Feb 27, 2026

Study contacts

Ahmed Elhaddad, Ass.prof.
Contact
drblacksmith@gmail.com
01224042847
Ahmed Elhaddad, Ass.prof.
principal investigator · Faculty of medicins,Cairo university

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Midazolam · Ketamine

Start the discussion